Boehringer Ingelheim Collaborates with Trutino Biosciences to Develop New Therapies Utilizing On-Demand-Cytokine Platform

 Boehringer Ingelheim Collaborates with Trutino Biosciences to Develop New Therapies Utilizing On-Demand-Cytokine Platform

Boehringer Ingelheim Collaborates with Trutino Biosciences to Develop New Therapies Utilizing On-Demand-Cytokine Platform

Shots:

  • Trutino to receive upfront, pre/ clinical milestones, regulatory and commercial milestones along with royalties on sales. Boehringer to get access for Trutino’s ODC platform to develop up to 3 new ODC cancer immunology candidates
  • The focus of the agreement is to develop more tolerable & effective cytokine therapies for single-agent and novel combinations with Boehringer’s cancer vaccine, oncolytic virus, T cell engager, and myeloid-targeting therapies
  • The collaboration will boost Boehringer’s immune-oncology portfolio by combining its breakthrough therapies with Trutino’s expertise in increasing the safety and efficacy of cytokine therapies

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: Boehringer Ingelheim

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post